⁠Canada’s Largest Drugmaker Grows 11% at Home as Comparable U.S. Revenue Falls 9%

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

Canada has become the strongest part of Apotex Health’s business at a moment when its U.S. operations are working through a more difficult product cycle. In its first-quarter fiscal 2027 results, covering the three months ended June 30, 2026, the Toronto-based pharmaceutical company reported Canadian revenue of C$413 million, up about 11% from a year earlier. Comparable U.S. revenue, excluding a large but temporary generic Revlimid contribution from the previous year, dropped roughly 9%.

The contrast shows how quickly fortunes can shift in the generic-drug industry. New launches are creating substantial opportunities in Canada, particularly around semaglutide, while competition and manufacturing-related interruptions are weighing on parts of the American portfolio. For Apotex, newly public after a major June IPO, the next challenge is proving that its growing pipeline can turn those uneven regional results into sustained company-wide expansion.

Canada Has Become Apotex’s Biggest Growth Engine

Apotex generated C$413 million of revenue in Canada during the quarter, C$43 million more than a year earlier. That 11% increase made Canada the company’s standout geographical market and represented nearly half of its C$848 million quarterly revenue. International revenue also increased, rising about 8% to C$72 million, but the Canadian business contributed considerably more dollars to the company’s overall growth.

The performance is notable for a company that has spent decades building an international generic-drug operation. Apotex sells hundreds of pharmaceutical and consumer-health products and operates in roughly 70 countries, yet its home market is currently doing much of the heavy lifting. New products were central to the Canadian improvement. Management specifically identified semaglutide as an important contributor, alongside growth in other areas of its portfolio. The result illustrates one advantage of being early with a major generic medicine: a successful launch can materially change the growth profile of even a multibillion-dollar pharmaceutical company.

Semaglutide Is Giving the Canadian Business New Momentum

One of the biggest developments behind Apotex’s Canadian momentum came in May, when it commercially launched Apo-Semaglutide Injection, a generic equivalent of Novo Nordisk’s Ozempic. Health Canada had authorized Apotex’s product shortly after Canada became the first G7 country to approve a generic semaglutide. Apotex’s version is indicated for adults with Type 2 diabetes and entered a market where semaglutide had already become one of the most closely watched medicines in the country.

Apotex expanded its opportunity again in June when Health Canada approved Sevmia, its generic equivalent of Wegovy for chronic weight management. That made Apotex the first company to receive Canadian approval for a generic semaglutide specifically for weight management. The timing matters commercially. Health Canada says generic medicines in Canada can often cost 45% to 90% less than their branded counterparts, depending on the product and market conditions. For pharmacies, public drug programs and patients, lower-priced versions of widely prescribed medicines can create significant demand once supply becomes established.

The 9% U.S. Decline Has Several Explanations

The American result looks considerably weaker. Excluding Apotex’s volume-limited generic Revlimid business, U.S. revenue declined by C$34 million, or approximately 9%, from the comparable period a year earlier. Management attributed the reduction partly to increased competition after market exclusivity expired for certain medicines, including nilotinib. That is a familiar challenge in generics: early entrants can enjoy an unusually attractive period before additional competitors arrive and push prices and market share lower.

A temporary pause in U.S. ophthalmic-product sales created another headwind. Apotex said the interruption was connected with remediation work at its Richmond Hill facility. New American launches provided some relief, particularly sitagliptin products, but they were not enough to offset the other pressures during the quarter. The distinction is important because the decline does not necessarily indicate that Apotex’s entire U.S. franchise is shrinking structurally. Instead, several product-specific events occurred simultaneously, exposing how volatile quarterly results can become when exclusivity periods end or manufacturing activity temporarily interrupts supply.

The Revlimid Comparison Makes Reported Revenue Look Much Worse

At first glance, Apotex’s consolidated revenue numbers appear far more troubling than either regional performance suggests. Reported first-quarter revenue fell 26% year over year, from about C$1.14 billion to C$848 million. The overwhelming reason was the disappearance of the previous year’s contribution from generic Revlimid, or lenalidomide. Apotex classifies the medicine as a volume-limited licence product, or VLLP, and excluded C$308 million of prior-year Revlimid revenue when presenting its underlying comparison.

Once that temporary contribution is removed, the picture changes substantially. Revenue excluding the VLLP increased approximately 2% to C$848 million from C$834 million. Investors therefore have two very different growth figures to consider: a reported decline of 26% and underlying growth of roughly 2%. Both are mathematically valid, but they tell different stories. The first captures what actually passed through the income statement; the second offers a better indication of how the continuing portfolio performed without a product management had already expected to fade.

Profitability Held Up Better Than the Headline Revenue Drop

Apotex generated adjusted EBITDA of C$259 million during the quarter, representing an adjusted EBITDA margin of approximately 31%. On a comparable basis excluding the prior Revlimid contribution, adjusted EBITDA was essentially stable from the previous year. That resilience matters because the mix of revenue changed sharply even as several higher-value product opportunities were being replaced or challenged by competition.

Other measures showed more pressure. Comparable gross profit fell 3% to C$421 million and the comparable gross margin slipped to about 50% from roughly 52%. Apotex attributed the change partly to product mix and higher inventory provisions, although productivity efforts helped through lower labour costs, procurement savings and manufacturing efficiencies. The company reported a net loss of C$38 million compared with C$363 million of net income in the year-earlier quarter, with higher finance expenses and lower gross profit among the factors. Share-based compensation associated with the IPO also drove selling, general and administrative expenses sharply higher.

The IPO Has Changed Apotex’s Financial Position

These results carry extra significance because they are Apotex’s first quarterly numbers as a publicly traded company. The drugmaker completed an upsized Toronto Stock Exchange IPO in June, selling more than 62 million shares at C$24 each after underwriters exercised their over-allotment option. The overall offering generated approximately C$1.495 billion in gross proceeds, although part of that amount went to existing shareholders rather than the company itself.

Apotex received about C$850 million in gross proceeds from the treasury portion of the transaction and subsequently said it applied C$800 million of IPO proceeds toward debt repayment. The balance-sheet changes were followed in July by an inaugural BBB (low) investment-grade issuer rating from Morningstar DBRS. Apotex also amended its financing arrangements, increasing its revolving credit facility to C$1.2 billion and extending its maturity. For a pharmaceutical manufacturer seeking more launches, acquisitions and manufacturing capacity, reducing leverage while expanding access to capital gives management considerably more flexibility than it had before the public listing.

Apotex Is Already Trying to Rebuild U.S. Growth

The weak U.S. quarter does not mean Apotex is retreating from the market. In June, the company launched generic sitagliptin tablets and sitagliptin-metformin tablets, alternatives to Januvia and Janumet, with both eligible for 180-day shared exclusivity. In July, it expanded its American hospital portfolio with four generic Infuvite adult and pediatric injectable products. Two received 180-day Competitive Generic Therapy exclusivity, potentially giving Apotex another period in which competition is more limited.

The company has also moved beyond conventional generics. On July 1, Apotex completed a US$100-million transaction involving Cumberland Pharmaceuticals’ U.S. branded business. The portfolio adds medicines used in acute care, oncology, infectious disease and gastroenterology, including products such as Caldolor, Sancuso and Acetadote. Separately, Apotex secured access to additional sterile injectable filling capacity at a New Jersey facility. Together, the moves suggest that management sees the answer to U.S. volatility not simply as selling more traditional generics, but as building a broader mix of hospital, specialty and branded medicines.

The Next Few Quarters Will Test the Growth Strategy

Apotex maintained its fiscal 2027 outlook despite the uneven first quarter. Management is targeting upper-mid-single-digit revenue growth, excluding the Revlimid-related VLLP, and an adjusted EBITDA margin of approximately 30%. New launches are expected to play an unusually important role: Apotex projects that products introduced during the year will generate roughly 10% of total fiscal-year revenue. Semaglutide in Canada, new U.S. exclusivity products and the Cumberland portfolio are among the main expected contributors.

Cost reductions are another piece of the plan. The company is targeting more than C$100 million of productivity savings during fiscal 2027, while simultaneously expanding its pipeline and manufacturing network. That creates a clear benchmark for the quarters ahead. Canada has demonstrated that a well-timed launch can produce double-digit regional growth. The U.S. has demonstrated the opposite lesson: exclusivity eventually disappears, competitors arrive and temporary production issues can quickly affect sales. Apotex’s challenge is to make its next wave of products arrive faster than older opportunities fade.

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.